3335 Intralesional administration of Coxsackievirus A21 (CVA21) oncolytic virus immunotherapy in patients with advanced melanoma induces durable tumor responses von Andtbacka, R.H.I, Curti, B, Kaufman, H.L, Daniels, G.A, Nemunaitis, J.J, Spitler, L.E, Hallmeyer, S, Lutzky, J, Schultz, S, Whitman, E.D, Zhou, K, Karpathy, R, Weisberg, J.I, Shafren, D

Volltext

Systemic Benefit of Gm-Csf-Encoding, Oncolytic Herpes Virus (Talimogene Laherparepvec, T-Vec) in Metastatic Melanoma: Phase Ii Assessment von Senzer, N., Bedell, C., Horvath, S., Nemunaitis, J.J.

Volltext

1059PSYSTEMIC BENEFIT OF GM-CSF-ENCODING, ONCOLYTIC HERPES VIRUS (TALIMOGENE LAHERPAREPVEC, T-VEC) IN METASTATIC MELANOMA: PHASE II ASSESSMENT von Senzer, N., Bedell, C., Horvath, S., Nemunaitis, J.J.

Volltext

Calm Study: Secondary Endpoints of a Phase Ii Study of a Novel Oncolytic Immunotherapeutic Agent, Coxsackievirus A21, Delivered Intratumorally in Patients with Advanced Malignant M... von Andtbacka, R.H., Curti, B., Kaufman, H., Daniels, G.A., Nemunaitis, J.J., Spitler, L.E., Hallmeyer, S., Lutzky, J., Schultz, S., Whitman, E.D., Zhou, K., Weisberg, J.I., Shafren, D.

Volltext

1103PCALM STUDY: SECONDARY ENDPOINTS OF A PHASE II STUDY OF A NOVEL ONCOLYTIC IMMUNOTHERAPEUTIC AGENT, COXSACKIEVIRUS A21, DELIVERED INTRATUMORALLY IN PATIENTS WITH ADVANCED MALIGN... von Andtbacka, R.H., Curti, B., Kaufman, H., Daniels, G.A., Nemunaitis, J.J., Spitler, L.E., Hallmeyer, S., Lutzky, J., Schultz, S., Whitman, E.D., Zhou, K., Weisberg, J.I., Shafren, D.

Volltext

1102PRESULTS OF THE EXTENSION TRIAL OF OPTIM, A MULTICENTER, RANDOMIZED PHASE 3 TRIAL OF TALIMOGENE LAHERPAREPVEC (T-VEC) VS GM-CSF FOR UNRESECTED STAGE IIIB-IV MELANOMA von Nemunaitis, J.J., Andtbacka, R.H., Ross, M., Amatruda, T., Chesney, J., Collichio, F.A., Harrington, K.J., Steven, N.M., Fourie, S., Dreosti, L., Li, A., Liu, K., Shilkrut, M., Coffin, R., Kaufman, H.

Volltext

Results of the Extension Trial of Optim, a Multicenter, Randomized Phase 3 Trial of Talimogene Laherparepvec (T-Vec) Vs Gm-Csf for Unresected Stage Iiib-Iv Melanoma von Nemunaitis, J.J., Andtbacka, R.H., Ross, M., Amatruda, T., Chesney, J., Collichio, F.A., Harrington, K.J., Steven, N.M., Fourie, S., Dreosti, L., Li, A., Liu, K., Shilkrut, M., Coffin, R., Kaufman, H.

Volltext

Gene Immunotherapy for Non-Small Cell Lung Cancer von Nemunaitis, John J. J.

Volltext

A phase II multicenter study of combined topotecan and gemcitabine as first line chemotherapy for advanced non-small cell lung cancer von Joppert, M.G, Garfield, D.H, Gregurich, M.A, Nemunaitis, J.J, Marsland, T.A, Khandelwal, P, Asmar, L

Volltext

Increased Macrophage Colony-Stimulating Factor Levels in Immune Thrombocytopenic Purpura von Zeigler, Z.R., Rosenfeld, C.S., Nemunaitis, J.J., Besa, E.C., Shadduck, R.K.

Volltext

Recombinant Tumor Necrosis Factor α and Interleukin 1α increase Expression of c-abl Protooncogene mRNA in Cultured Human Marrow Stromal Cells von Andrews, D. Frank, Nemunaitis, John J., Singer, Jack W.

Volltext

Adenovirus-Mediated p53 Gene Transfer in Sequence With Cisplatin to Tumors of Patients With Non–Small-Cell Lung Cancer von NEMUNAITIS, J, SWISHER, S. G, FOSSELLA, F, GLISSON, B. S, HONG, W. K, KHURI, F. R, KURIE, J. M, LEE, J. J, LEE, J. S, NGUYEN, D. M, NESBITT, J. C, PEREZ-SOLER, R, TIMMONS, T, PISTERS, K. M. W, PUTNAM, J. B, RICHLI, W. R, SHIN, D. M, WALSH, G. L, MERRITT, J, ROTH, J, CONNORS, D, MACK, M, DOERKSEN, L, WEILL, D, WAIT, J, LAWRENCE, D. D, KEMP, B. L

Volltext